A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

The primary objective of this study is to evaluate the efficacy of ibrutinib in combination
with obinutuzumab compared to chlorambucil in combination with obinutuzumab based on the
Independent Review Committee (IRC) assessment of progression free survival (PFS). Efficacy
will be evaluated according to 2008 International Workshop for Chronic Lymphocytic Leukemia
(IWCLL) criteria with the modification for treatment-related lymphocytosis, in subjects with
treatment-naive CLL or SLL.